Literature DB >> 22237142

miR-34a expression, cell cycle arrest and cell death of malignant mesothelioma cells upon treatment with radiation, docetaxel or combination treatment.

Taha Ghawanmeh1, Ulf Thunberg, Juan Castro, Fiona Murray, Nongnit Laytragoon-Lewin.   

Abstract

OBJECTIVE: Malignant mesothelioma (MM) is a highly aggressive tumour related to asbestos exposure. Histopathologically, the tumour is classified as epithelial, sarcomatoid or biphasic. To date, MM is still an incurable disease.
METHODS: To evaluate treatment strategies on MM cells, the effects of radiotherapy, docetaxel or a combination of both on MM cells derived from the sarcomatoid type ZL34 and the epithelial type M28K were investigated. The TP53 gene, micro-RNA expression, cell cycle distribution and cell death were assessed as indicators of treatment effects.
RESULTS: Despite the normal TP53 gene sequences in these cell lines, radiation-induced miR-34a expression was detected only in the M28K cells. Increasing G0/G1 cell numbers were detected in irradiated M28K and ZL34 cells. There was more radiation-induced cell death in M28K compared to ZL34 cells. The highest degree of cell cycle arrest at G2 and cell death in both cell types was obtained in the presence of docetaxel. The combination of docetaxel and radiation did not show any additive effects on miR-34a expression, cell cycle arrest or cell death in either the M28K or ZL34 cells.
CONCLUSION: Microtubule formation and other related functions by docetaxel might be the most suitable treatment modulation in both sarcomatoid and epithelial types of MM.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22237142     DOI: 10.1159/000334237

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  14 in total

1.  MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1.

Authors:  Laisheng Li; Linjin Yuan; Jinmei Luo; Jie Gao; Jiaoli Guo; Xiaoming Xie
Journal:  Clin Exp Med       Date:  2012-05-24       Impact factor: 3.984

2.  Selection of reference genes for miRNA quantitative PCR and its application in miR-34a/Sirtuin-1 mediated energy metabolism in Megalobrama amblycephala.

Authors:  Jie Liu; Erteng Jia; Huajuan Shi; Xiangfei Li; Guangzhen Jiang; Cheng Chi; Wenbin Liu; Dingdong Zhang
Journal:  Fish Physiol Biochem       Date:  2019-05-24       Impact factor: 2.794

3.  microRNA-34a promotes DNA damage and mitotic catastrophe.

Authors:  Alexander V Kofman; Jungeun Kim; So Yeon Park; Evan Dupart; Christopher Letson; Yongde Bao; Kai Ding; Quan Chen; David Schiff; James Larner; Roger Abounader
Journal:  Cell Cycle       Date:  2013-09-19       Impact factor: 4.534

Review 4.  New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.

Authors:  Brooke T Mossman; Arti Shukla; Nicholas H Heintz; Claire F Verschraegen; Anish Thomas; Raffit Hassan
Journal:  Am J Pathol       Date:  2013-02-08       Impact factor: 4.307

5.  Novel drug delivery system based on docetaxel-loaded nanocapsules as a therapeutic strategy against breast cancer cells.

Authors:  Paola Sánchez-Moreno; Houria Boulaiz; Juan Luis Ortega-Vinuesa; José Manuel Peula-García; Antonia Aránega
Journal:  Int J Mol Sci       Date:  2012-04-19       Impact factor: 6.208

6.  MiR-34a inhibits migration and invasion by regulating the SIRT1/p53 pathway in human SW480 cells.

Authors:  Mingguang Lai; Gang Du; Ruiyue Shi; Jun Yao; Genhua Yang; Yue Wei; Dingguo Zhang; Zhenglei Xu; Ru Zhang; Yingxue Li; Zicheng Li; Lisheng Wang
Journal:  Mol Med Rep       Date:  2015-01-12       Impact factor: 2.952

7.  microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma.

Authors:  Robert Fred Henry Walter; Claudia Vollbrecht; Robert Werner; Jeremias Wohlschlaeger; Daniel Christian Christoph; Kurt Werner Schmid; Fabian Dominik Mairinger
Journal:  Oncotarget       Date:  2016-04-05

8.  Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a.

Authors:  Jiaoli Guo; Wenping Li; Hongliu Shi; Xinhua Xie; Laisheng Li; Hailin Tang; Minqing Wu; Yanan Kong; Lu Yang; Jie Gao; Peng Liu; Weidong Wei; Xiaoming Xie
Journal:  Mol Cell Biochem       Date:  2013-06-15       Impact factor: 3.396

Review 9.  miR-34: from bench to bedside.

Authors:  Massimiliano Agostini; Richard A Knight
Journal:  Oncotarget       Date:  2014-02-28

10.  In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation.

Authors:  Maria Angelica Cortez; David Valdecanas; Sharareh Niknam; Heidi J Peltier; Lixia Diao; Uma Giri; Ritsuko Komaki; George A Calin; Daniel R Gomez; Joe Y Chang; John Victor Heymach; Andreas G Bader; James William Welsh
Journal:  Mol Ther Nucleic Acids       Date:  2015-12-15       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.